ETFs To Watch On Strong Earnings From Pharma Companies [Pfizer Inc., Merck & Co., Inc., Eli Lilly and Co]

healthcare1The pharma space has been seeing smooth trading thanks to encouraging industry trends such as development of new drugs, the rising wave of mergers and acquisitions, increased need for medical services, expansion into emerging markets and the Affordable Care Act (often known as Obamacare). Further, strong earnings from pharma players are fueling growth in the sector.

Johnson & Johnson (JNJ) was the first major drug company to report second-quarter earnings. It reported earnings and revenues with a huge bang on July 15, spreading optimism into the sector. Another chain of forecast-beating earnings from the industry primes like Pfizer (PFE), Merck (MRK), Eli Lilly and Company (LLY) and Bristol-Myers Squibb Company (BMY) is again building up confidence in the sector (read: Healthcare ETFs in Focus on JNJ Earnings).

PFE Earnings in Focus

Earnings per share came in at 58 cents, a couple of cents ahead of the Zacks Consensus Estimate and 4% above the year-ago earnings. Revenues dropped 2% year over year to $12.77 billion but surpassed the Zacks Consensus Estimate of $12.4 billion thanks to growing sales of its cancer medicines.

For 2014, the U.S. drug maker giant reiterated the earnings per share guidance at $2.20–$2.30 but reduced the revenue guidance to $48.7–$50.7 billion from $49.2–$51.2 billion due to the earlier-than-expected arrival of generic competition for arthritis drug Celebrex in December. The Zacks Consensus Estimates for earnings and revenues are currently $2.25 per share and $50.11 billion, respectively.

Shares of PFE ended the day in the red, losing 1.2% on elevated volume.

MRK Earnings in Focus

The second largest U.S. drug maker reported earnings per share of 85 cents outpacing our estimate by 4 cents and improving 1.2% from the year-ago earnings. Though revenue slipped 1% to $10.9 billion, it is well above the Zacks Consensus Estimate of $10.7 billion. Better-than expected performance was buoyed by strong sales of consumer products and medicines for arthritis and HIV.

Merck projects revenue of $42.4-$43.2 billion and earnings per share in the range of $3.43–$3.53 for 2014. The Zacks Consensus Estimate for revenue and earnings are currently $42.63 billion and $3.49 per share, respectively.

The stock gained about 1% in Tuesday trading after its earnings announcement (read: A Comprehensive Guide to Pharma ETFs).

LLY Earnings in Focus

Eli Lilly topped the Zacks Consensus Estimate on both the top and bottom lines. Earnings per share of 68 cents and revenue of $4.94 were ahead of our earnings estimate by a couple of cents and revenue estimate by $0.11 billion. The company reiterated its earnings per share guidance of $2.72–$2.80 on revenues of $19.4–$20.0 billion. The Zacks Consensus Estimate for earnings and revenue are currently of $2.79 and $19.7 billion, respectively.

Shares of LLY are down 2.5% post earnings announcement on July 24.

BMY Earnings in Focus

Second quarter earnings for Bristol-Myers Squibb beat the Zacks Consensus Estimate by four cents but revenue of $3.89 billion slightly missed our estimate of $3.92. The company maintained its 2014 revenue guidance of $15.2-$15.8 billion and earnings per share guidance of $1.70-$1.80. The Zacks Consensus Estimates for revenue and earnings are currently of $15.5 billion and $1.78, respectively.

The shares of BMY are up 3.1% post its earnings announcement on July 24.

ETF Angle

Though these firms beat on earnings, they have given mixed performances depending on their specific fundamentals and dragged down pharma ETFs. Given this, the pharma ETFs having largest allocation to these drug makers are currently in focus.

Pages: 1 2

Leave a Reply

Your email address will not be published. Required fields are marked *